Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells

Peptides

Volumn 28, Issue 9, 2007, Pages 1883-1890

  Moody, Terry W ^a   Mantey, Samuel A ^b   Fuselier, Joseph A ^c   Coy, David H ^c   Jensen, Robert T ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Breast cancer; Camptothecin; Cellular proliferation; Receptor mediated cytotoxicity; VIP receptors

Indexed keywords

CAMPTOTHECIN; CARBAMIC ACID; CYCLIC AMP; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE[2,8,9,19,24.25.27 ALANINE 17 NORLUECINE 28 LYSINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[2,8,9,19,24.25.27 ALANINE 17 NORLUECINE 28 LYSINE] N METHYLAMINOETHYLGLYCINE; VASOACTIVE INTESTINAL POLYPEPTIDE[2,8,9,19,24.25.27 ALANINE 17 NORLUECINE 28 LYSINE] N METHYLAMINOETHYLGLYCINE CAMPTOTHECIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN 3T3; CELL STRAIN MCF 7; CHEMICAL BOND; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SYNTHESIS;

3T3 CELLS; ANIMALS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 34548504526     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.04.017     Document Type: Article

References (48)

1. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Peptides 37 (1992) 287-303
2. Buchholz S., Keller G., Schally A.V., Halmos G., Hohla F., Heinrich E., et al. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proc Natl Acad Sci USA 103 (2006) 10403-10407
3. 2 and VIP increase VEGF mRNAs in lung cancer cells. Lung Cancer 31 (2001) 203-212
4. Cha S.W., Gu H.K., Lee K.P., Lee M.H., Han S.S., and Jeong T.C. Immunotoxicity of ethylcarbamate in female BALB/C mice: role of esterase and cytochrome P450. Toxicol Lett 115 (2000) 173-181
5. 50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
6. deGroot F.M., Damen E.W., and Scheeren H.W. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem 8 (2001) 1093-1122
7. Dickson R.B., Pestell R.G., and Lippman M.E. Molecular biology of breast cancer. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology (2006), Lippincott, Williams and Wilkins, Philadelphia 1399-1414
8. Dubowchik G.M., and Walker M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 83 (1999) 67-123
9. Fahrenkrug J. Glycine-extended processing intermediate of proVIP: a new bioactive form of VIP in the rat. Biomed Res 13 Supl 2 (1992) 19-23
10. Fisher B., Constantino J.P., Wickerham D.L., Cecchini W.M., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer. Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 97 (2005) 1652-1662
11. Fuselier J.A., Sun L., Woltering S.N., Murphy W.A., Vasilevich N., and Coy D.H. An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett 13 (2003) 799-803
12. Garcia-Fernandez M.O., Bodega G., Ruiz-Villaespesa A., Cortes J., Prieto J.C., and Carmena M.J. PACAP expression and distribution in human breast cancer and healthy tissue. Cancer Let 205 (2004) 189-195
13. Garcia-Fernandez M.O., Collado B., Bodega G., Cortes J., Ruiz-Villaespesa A., Carmena M.J., et al. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue. Gynecol Endocrinol 20 (2005) 327-333
14. Gelber E., Granoth R., Fridkin M., Dreznik Z., Brenneman D.E., Moody T.W., et al. A lipophilic vasoactive intestinal analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer 92 (2001) 2172-2180
15. Gespach C., Bawab W., Decremox P., and Calvo F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res 48 (1988) 5079-5083
16. Gozes I., Davidson A., Draoui M., and Moody T.W. The VIP gene is expressed in non small cell lung cancer cell lines. Biomed Res 13 (1993) 37-40
17. Gozes I., McCune S.L., Jacobson L., Warren D., Moody T., Fridkin M., et al. A hybrid antagonist to vasoactive intestinal peptide. Effects on cellular function in the central nervous system. J Pharmacol Exp Ther 257 (1991) 959-966
18. Harmar T., and Lutz E.M. Multiple receptors for PACAP and VIP. Trends Pharmacol Sci 15 (1993) 97-99
19. 1 receptors in human, rat and guinea pig. J Pharmacol Exp Ther 301 (2002) 37-50
20. Igarashi H., Ito T., Mantey S.A., Pradhan T.K., Hou W., Coy D.H., et al. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors. J Pharmacol Exp Ther 315 (2005) 370-381
21. 1 receptors. J Pharmacol Exp Ther 302 (2002) 445-460
22. Ishihara R., Shigemoto R., Mori K., Takahashi K., and Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8 (1992) 811-819
23. Laburthe M., Couvineau A., and Marie J.C. VPAC receptors for VIP and PACAP. Receptors Channels 8 (2002) 137-153
24. 13,14)bombesin analogues inhibit the growth of small cell lung cancer in vitro and in vivo. Cancer Res 51 (1991) 1298-1302
25. Moody T.W., Chan D., Fahreenkrug J., and Jensen R.T. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Design 9 (2003) 495-509
26. Moody T.W., Czerwinski G., Tarasova N.I., and Michejda C.J. VIP-ellipticine derivatives inhibit the growth of breast cancer cells. Life Sci 71 (2002) 1005-1014
27. Moody T.W., Fuselier J., Coy D.H., Mantey S., Pradhan T., Nakagawa T., et al. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides 26 (2005) 1560-1566
28. Moody T.W., Hill J.M., and Jensen R.T. VIP as a trophic factor in the CNS and cancer cells. Peptides 24 (2003) 163-177
29. 1 receptors. Ann NY Acad Sci 1070 (2006) 636-639
30. Moody T.W., and Jensen R.T. VIP and PACAP as autocrine growth factors in breast and lung cancer. In: Kastin A. (Ed). Handbook of biologically active peptides (2006), Elsevier Science, London 493-498
31. Moody T.W., Leyton J., Chan D., Brenneman D.E., Fridkin M., Gelber E., et al. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat 68 (2001) 55-64
32. Moody T.W., Sun L.C., Mantey S.A., Pradhan T., Mackey L.V., Gonzales N., et al. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther 318 (2006) 1265-1272
33. Moody T.W., Mantey S.A., Pradhan T.K., Schumann M., Nakagawa T., Martinez A., et al. Development of high affinity camptothecin-bombesin conjugates which have targeted cytotoxicity for bombesin receptor-containing cells. J. Biol. Chem 279 (2004) 23580-23589
34. Moody T.W., Zia F., Draoui M., Brenneman D.E., Fridkin M., Davidson A., et al. A novel VIP antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci USA 90 (1993) 4345-4349
35. Nagy A., and Schally A.V. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr Pharm Des 11 (2005) 1167-1180
36. 1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 275 (2000) 24003-24012
37. Patterson L.H., McKeown S.R., Robson T., Gallagher R., Raleigh S.M., and Orr S. Antitumor prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des 14 (1999) 473-474
38. Pisegna J.R., and Wank S.A. Multiple cloning and functional expression of the pituitary adenylate cyclase activating polypeptide type I receptor. Proc Natl Acad Sci USA 90 (1993) 6345-6349
39. Reubi J.C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 36 (1995) 1846-1853
40. Reubi J.C., Laderach U., Waser B., Gebbers J.D., Robberecht P., and Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor subtypes in human tumors and their tisssues of origin. Cancer Res 60 (2000) 3105-3112
41. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from the small intestine. Science 69 (1970) 1217-1218
42. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeberg P.H., et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365 (1993) 170-175
43. Sun L., Fuselier J.A., and Coy D.H. Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents. Drug Deliv 11 (2004) 231-238
44. Tripathy D., Slamon D.J., Cobleigh M., Arnold A., Saleh M., Mortimer J.E., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22 (2004) 1063-1070
45. Waschek J.A., Richards M.I., and Bravo D.T. Differential expression of VIP/PACAP receptor genes in breast, intestinal and pancreatic cell lines. Cancer Res 92 (1995) 143-149
46. Whitmarsh A.J., and Davies R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74 (1996) 589-607
47. Wood W.D., Muss H.B., Solin L.J., and Olopade O. Malignant tumors of the breast. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology (2006), Lippincott, Williams and Wilkins, Philadelphia 1415-1477
48. Zia H., Hida T., Jakowlew S., Birrer M., Gozes Y., Reubi J.C., et al. Breast cancer growth is inhibited by VIPhybrid, a synthetic VIP receptor antagonist. Cancer Res 56 (1996) 3486-3489